Weighted-Average Shares Outstanding (Diluted): The number of shares held by shareholders including insiders but not including a company's treasury shares assuming conversion of all convertible debt, securities, warrants and options, sourced from the company 10-K or 10-Q SEC reports.
Gain Therapeutics, Inc. (GANX) had Weighted-Average Shares Outstanding (Diluted) of 42.88M for the most recently reported fiscal quarter, ending 2026-06-30.
| Income Statement Financials | |
-- |
|
$-4.68M |
|
-- |
|
-- |
|
$4.68M |
|
$-4.68M |
|
$0.11M |
|
$-4.57M |
|
$-4.57M |
|
$-4.68M |
|
$-4.68M |
|
$-4.68M |
|
$-4.68M |
|
$-4.68M |
|
$-4.65M |
|
42.88M |
|
|
Weighted-Average Shares Outstanding (Diluted) |
42.88M |
$-0.11 |
|
$-0.11 |
|
| Balance Sheet Financials | |
$14.97M |
|
$0.05M |
|
$0.45M |
|
$15.42M |
|
$3.43M |
|
$0.22M |
|
$0.70M |
|
$4.13M |
|
$11.29M |
|
$11.29M |
|
$11.29M |
|
43.34M |
|
| Cash Flow Statement Financials | |
$-9.41M |
|
-- |
|
$1.77M |
|
$20.87M |
|
$13.12M |
|
$-7.75M |
|
$0.97M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
4.36 |
|
-- |
|
-- |
|
0.02 |
|
0.03 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-9.41M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-41.41% |
|
-41.41% |
|
-30.32% |
|
-40.61% |
|
$0.26 |
|
$-0.22 |
|
$-0.22 |
|